Roche has signed a deal with Alector that includes a $100 million upfront payment, targeting Alector’s neuroscience and Parkinson’s disease programs. The agreement arrives after another large pharma partnership reportedly collapsed, putting renewed emphasis on Roche’s continued efforts to build out CNS exposure through biotech collaborations. The transaction’s structure centers on Alector’s platform and pipeline in Parkinson’s disease, with the upfront payment reflecting early-stage value while preserving flexibility for Roche on later development and commercialization decisions. The move also signals that large drugmakers remain willing to fund late discovery work when targets and mechanisms align with internal therapeutic priorities. For Alector, the cash infusion provides runway while it develops its neurodegeneration candidates—an area where trial timelines and biomarker strategies often dictate how quickly deals translate into clinical outcomes.